ABSTRACT
Poor medication adherence continues to be a major challenge in today's health care system. Although many factors likely contribute to poor adherence, studies have suggested that out-of-pocket (OOP) cost might be highly influential. [1] [2] [3] [4] [5] OOP cost has been identified as a barrier to the use of blood-pressure-lowering regimens and statins, 2, 3, [5] [6] [7] [8] [9] [10] resulting in poor disease control and unfavourable clinical outcomes. 2, [7] [8] [9] [10] In fact, it has been suggested that increasing OOP costs result in higher overall health care spending through higher physician visits, emergency department visits, and hospitalizations. 2, 6, 7, 9 As a result, a reasonable strategy to combat rising health care costs might be to increase spending on drug insurance plans to help improve medication adherence among their beneficiaries.
Several observational studies have linked lower OOP costs with higher medication adherence and reduced spending on health care services. [11] [12] [13] [14] [15] Chernew and colleagues reported that reduced OOP costs increased adherence up to 14% following a reduction in OOP costs by 50-100%, 16 whereas smaller improvements in adherence (4-6%) were observed in a randomized trial testing the benefits of providing cardiac medications free of charge. 4 In the latter study, significant reductions in total major vascular events or revascularizations was found among subjects receiving free medications during a follow-up period of three years following a myocardial infarction. 4 These studies suggest that investing in medication costs has positive benefits; 4 however, previous research has produced highly variable estimates about the impact of reducing OOP cost at the population level. 4, 16 On July 1 st , 2007, the Saskatchewan government launched the Senior's Drug Plan benefit (SDP) to reduce seniors' OOP costs to a maximum of $15 per prescription for all medications listed in the provincial drug formulary. This province-wide intervention represented another opportunity to study the impact of OOP cost reduction at the population level. The purpose of this study was to estimate the impact of the SDP on medication adherence for major chronic conditions in Saskatchewan.
METHODS

Data Source
The Saskatchewan Ministry of Health maintains several databases including a person registry, a prescription database, a Hospital Discharge Abstract Database (DAD), and a physician services claims database. These databases can be linked by the unique identification number derived from each individual's encrypted health service number.
17,18
The prescription database captures all outpatient dispensations to beneficiaries for medications listed in an extensive benefit list. Over 90% of the population are registered beneficiaries, excluding individuals receiving drug benefits from the federal government (e.g., First Nations or Canadian Armed Forces). The prescription database does not capture information for prescriptions excluded from the benefit list, physician samples, over-the-counter (OTC) drugs, or medications used during hospitalization. 17 The physician services database contains all claims by physicians providing service under a fee-for-service model; each claim contains a 3-digit ICD-9 diagnostic code. The hospital discharge abstract database records information on every discharge, transfer, or death of an inpatient. Diagnoses are recorded using the ICD-10-CA classification system since 2001 [18] [19] [20] and each hospital discharge record can record up to 25 diagnoses 18, 21 and up to 20 procedures . 18, 22 Overall, Saskatchewan health-administrative databases have been used frequently in health services research and provide valid information on diagnoses and drug use. . For subjects receiving more than one eligible medication (e.g., cholesterol-lowering agent and blood-pressure lowering agent), pharmacy claims of each medication type were followed up as separate observations. Patients were excluded if they were not continuous drug-plan beneficiaries for at least one-year before and one-year after the earliest dispensation for a target medication during the study period.
Previous studies have clearly demonstrated that adherence levels decline much faster among incident users 27, 28 ; therefore, separate analyses were carried out for incident and prevalent users of chronic medications. Incident users were defined by no dispensations within the same therapeutic category during 365 days prior to the index date.
Adherence Outcome Measures:
Medication adherence was estimated using the Medication Possession Ratio (MPR) with the exception that 'days supplied' was not available to investigators so it had to be estimated. 29 For statin, ACE inhibitors/ angiotensin receptor blockers (ACEI/ARB), and antidepressants, the number of days supplied for each dispensation was fixed at 34 days corresponding to the typical refill duration by Saskatchewan pharmacies. 30 This approach has been used previously to assess medication adherence with good consistency with other measures. 29 For the oral blood-glucose-lowering agents (metformin, and glyburide), the number of days supplied was defined according to an algorithm based on the dispensed quantity (Appendix 1) because the maintenance drug schedule of the Saskatchewan drug plan formulary allows up to 100-day supplies to be dispensed for these agents. 31 The MPR was calculated as the total of all dayssupplied between the index date and the following 365 days, divided by 365 to obtain an adherence percentage. Hospitalized days were subtracted from the denominator because medication use cannot be captured for inpatients. 32, 33 Adherence values were truncated to 100% but values exceeding 120% were manually examined to identify possible misclassification. Individuals switching within the same medication class were considered continuous users.
Data Analyses
Generalized estimating equations (GEE) with an exchangeable working correlation structure were constructed to test the impact of the SDP on the endpoint of optimal adherence (i.e., MPR ≥ 80%) at one year. This definition is the most frequently applied criteria in medication adherence studies. 34, 36 Covariates (Appendix 2) were identified according to a framework of adherence determinants by the World Health Organization, 24, [37] [38] [39] [40] [41] [42] and all were included in the multivariable model to minimize the risk of confounding in the comparison of adherence between the pre-SDP and post-SDP cohorts. To quantify the impact of the SDP, an interaction term was created between TIME (i.e., before/after the SDP) and age category (i.e., <65/≥65) because only those ≥65 were exposed to the SDP in the 'after period'. The null hypothesis asserted that the impact of TIME (before vs after) was not impacted by one's age (≥65 versus <65), whereas the alternative hypothesis is that the impact of TIME would depend on a person's age because only those ≥65 received the SDP in the post-period. The odds ratios (OR) and 95% confidence intervals for the impact of the SDP were determined from the equation e β where β represents the coefficient for the interaction term.
Subgroup analyses were conducted based on type of medication, sex, age, hospitalization (0 vs. ≥ 1 hospitalized days during the observation period), and medication cost (<$15, $15-30 and >$30) using the Reduced Out-of-Pocket Costs and Medication Adherence e4 same modelling approach described above. In addition, several sensitivity analyses were carried out on the estimation of MPR. Specifically, the number of days supplied for each dispensation was estimated using alternative methods to determine if the specific approach impacted the results. For example, statins are most commonly prescribed as one tablet/capsule per day; thus, the number of days supplied of each statin dispensation was estimated by using the quantity dispensed instead of the fixed estimate of 34 days per each dispensation. 43 However, the risk for bias originating from any of the MPR calculations was felt to be low because the approach was consistently applied to all cohorts in each model. SAS statistical software, version 9.3, (SAS Institute Inc., Cary, NC, USA) was used to conduct all analyses. Population adherence rates were measured before versus after the implementation of the SDP (i.e., preversus post-SDP). In addition, patients <65 years of age who did not receive SDP benefits in either period (pre or post) were included in the analysis to control for the effect of time. Within both subgroups of patients (≥65 and <65) baseline differences between the pre-SDP period and the post-SDP period were rarely of clinical importance (Table 1 ). ACEI and ARBs were the most frequently used medications in both age groups (≥65 and <65), followed by statins (see Table 1 ). On average, patients ≥65 received five different medications within the first three months of observation. In terms of adherence, a weighted mean improvement of 2.59% was observed in the senior's group before versus after the implementation of the SDP (unadjusted) compared to 0.75% among those <65 years over the same period (Table 2) .
After multivariate adjustment, the SDP program was associated with a small but statistically significant increase in the odds of optimal adherence for seniors ≥65 years of age receiving their medications in the post-SDP period (OR = 1.08, 95% CI: 1.04 to 1.11) compared to the pre-SDP period. The association between the SDP benefit and higher adherence was strengthened by the results of several subgroup analyses. First, a slight reduction in the odds of optimal adherence was observed in the cohort of patients <65 years of age who did not receive SDP benefits (OR = 0.96, 95% CI: 0.94 to 0.98). Also, no impact of the SDP was observed among patients with medications costing less than $15 (OR = 0.97, 95% CI: 0.86 to 1.11) or those receiving discounted dispensations due to another government plan with self-payment less than $15 (OR = 0.94, 95% CI: 0.89 to 1.01). In contrast, the impact of the SDP on adherence was consistently demonstrated in subgroups of patients receiving medications costing between $16 and $30 (OR = 1.24, 95% CI: 1.08 to 1.41) as well as those costing ≥ $30 (OR = 1.21, 95% CI: 1.16 to 1.26). After excluding individuals who were already receiving medication benefits from other government programs, the odds of achieving optimal adherence increased by 21% following SDP implementation (OR = 1.21, 95% CI: 1.16 to 1.26, Figure 2 ) Finally, the SDP was significantly associated with higher odds of achieving good adherence for prevalent users of chronic medications (OR of prevalent users = 1.08, 95% CI: 1.04 to 1.12), but not for incident users (OR of incident users = 1.05, 95% CI: 0.98 to 1.13). When cohorts were stratified by medication class, blood-cholesterol-lowering agents (i.e., statin), bloodpressure-lowering medications (i.e., ACEI/ARB), the blood-glucose-lowering agent metformin, and the SSRIs were significantly impacted by the SDP (Figure 3) . Although all OR values were higher than one, the odds of achieving optimal adherence for the other medication classes did not reach statistical significance.
Several sensitivity analyses were conducted to ensure that the primary results were not influenced by methodologic approaches. Consistent results were obtained with alternative estimation on supply days (by dispensation quantity), and different thresholds of optimal adherence (MPR of 50% to 100%) Also, the results were consistent when the original cohort was expanded by 131,637 observations of 48,797 unique patients who were originally excluded due to missing residency and income information.
DISCUSSION
This retrospective study examined the impact of a drug benefit program for seniors in Saskatchewan, Canada where OOP costs for most prescription medications were capped at $15. A statistically significant improvement in medication adherence was observed following the implementation of the SDP benefit in Saskatchewan (OR 1.08; 95% CI 1.04 to 1.11). The impact of SDP on adherence was larger in patients with higher drug costs and in patients who had previously received the same drug without the SDP benefit (i.e., prevalent users). In absolute terms, the improvement in medication adherence following SDP implementation was small. However, these findings are consistent with current paradigms describing non-adherence as a multifactorial problem. In other words, simply reducing one single factor (such as cost) does not drastically impact overall adherence levels. 45 A similar finding was reported by Choudhry and colleagues who found that full coverage for medications resulted in a 5% increase in the percentage of patients with optimal adherence (i.e., from 39% to 44%). 4 The SDP affected prevalent medication users but not incident users. Several possible reasons for these results can be theorized. First, adherence levels decline much faster among incident users. 28 Thus, it is possible that the relative importance of cost may be diluted in the early phases of therapy when numerous other adherence barriers such as tolerability, attitudes, beliefs, and knowledge may be more impactful. On the other hand, prevalent users witnessed a direct reduction in the cost of their medications following the SDP launch. Perhaps this obvious cost reduction motivated a slight improvement in adherence for the following year. Most importantly, this study was restricted to a one-year period of adherence assessment so it is not known whether these small increases in adherence were sustained over the long term.
The evaluation of the SDP used comprehensive population based databases and produced results that were verified in sensitivity analyses. However, several limitations must be recognized. First, the presence of private medication coverage is not captured in Saskatchewan's health-administrative databases. Thus, we cannot be certain of the OOP costs paid by beneficiaries. However, rates of private insurance were not likely to have changed between seniors starting medications before versus after the SDP. Further, considering all individuals are over the age of 65, drug coverage from private insurance through employment is expected to be low. Secondly, the indicators of medication use are based on electronic refill databases, which are indirect measures of drug consumption. However, studies suggest that refill claims are highly concordant to actual intake. 49 Thirdly, only a one-year period of adherence was examined for individuals taking chronic medications. It is not clear whether the small impacts of the SDP would be sustained over a long-term follow-up period. Fourth, the impact of the SDP on medication adherence was restricted to a few classes of chronic medications only. Measurement of adherence to all types of medication classes would not be feasible. Moreover, many medication classes such as antibiotics and pain medications are not meant to be taken chronically. However, the medications examined in this study represented the most commonly used chronic medications in Canada and corresponded to the diseases of highest prevalence in elderly patients. Lastly, we did not control for each individual's overall medication cost. Hypothetically, the benefit of the SDP may have been greater among seniors receiving multiple medications because of greater savings on total medication costs. It would be interesting to conduct further analyses in this regard.
In conclusion, the SDP was associated with a statistically significant improvement in medication adherence for specific chronic medications; however, it remains unknown if these small improvements have translated into health benefits and/or economic savings for downstream health care services. Regardless, cost reduction for seniors in Saskatchewan must have provided substantial relief independent of the impact on adherence and utilization.
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